JP2009541239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541239A5 JP2009541239A5 JP2009515768A JP2009515768A JP2009541239A5 JP 2009541239 A5 JP2009541239 A5 JP 2009541239A5 JP 2009515768 A JP2009515768 A JP 2009515768A JP 2009515768 A JP2009515768 A JP 2009515768A JP 2009541239 A5 JP2009541239 A5 JP 2009541239A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- component
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006186 oral dosage form Substances 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 10
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 8
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229960004601 aliskiren Drugs 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 8
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 208000021908 Myocardial disease Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 239000004067 bulking agent Substances 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229940100445 wheat starch Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940096516 dextrates Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940044025 aliskiren 300 mg Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0612540.5 | 2006-06-23 | ||
| GBGB0612540.5A GB0612540D0 (en) | 2006-06-23 | 2006-06-23 | Galenical formulations of organic compounds |
| PCT/EP2007/005476 WO2007147596A1 (en) | 2006-06-23 | 2007-06-21 | Galenical formulations of aliskiren and hydrochlorothiazide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541239A JP2009541239A (ja) | 2009-11-26 |
| JP2009541239A5 true JP2009541239A5 (enExample) | 2010-08-12 |
| JP5362556B2 JP5362556B2 (ja) | 2013-12-11 |
Family
ID=36803824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515768A Expired - Fee Related JP5362556B2 (ja) | 2006-06-23 | 2007-06-21 | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8618172B2 (enExample) |
| EP (3) | EP2034968B1 (enExample) |
| JP (1) | JP5362556B2 (enExample) |
| KR (1) | KR101442272B1 (enExample) |
| CN (1) | CN101472566A (enExample) |
| AR (1) | AR061565A1 (enExample) |
| AU (1) | AU2007263261B2 (enExample) |
| BR (1) | BRPI0713338A2 (enExample) |
| CA (1) | CA2654872A1 (enExample) |
| CL (1) | CL2007001837A1 (enExample) |
| EC (1) | ECSP088986A (enExample) |
| ES (1) | ES2704979T3 (enExample) |
| GB (1) | GB0612540D0 (enExample) |
| GT (1) | GT200800297A (enExample) |
| IL (1) | IL195425A (enExample) |
| MA (1) | MA30527B1 (enExample) |
| MX (1) | MX2008016533A (enExample) |
| MY (1) | MY146779A (enExample) |
| NO (1) | NO20090262L (enExample) |
| NZ (1) | NZ572937A (enExample) |
| PE (2) | PE20120990A1 (enExample) |
| RU (1) | RU2491058C2 (enExample) |
| TN (1) | TNSN08528A1 (enExample) |
| TW (1) | TWI457137B (enExample) |
| WO (1) | WO2007147596A1 (enExample) |
| ZA (1) | ZA200809773B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2483718C2 (ru) * | 2007-09-28 | 2013-06-10 | Новартис Аг | Галеновые композиции алискирена |
| EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
| JP2010031006A (ja) * | 2008-07-17 | 2010-02-12 | Novartis Ag | 有機化合物の使用 |
| ES2365429B1 (es) | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| CN102626391B (zh) * | 2012-04-19 | 2013-07-10 | 海南美兰史克制药有限公司 | 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂 |
| US9301918B2 (en) * | 2013-03-15 | 2016-04-05 | Mallinckrodt Llc | Abuse deterrent solid dosage form for immediate release with functional score |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6010719A (en) | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
| PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| IS1935B (is) * | 2002-03-19 | 2004-06-16 | Actavis Group Hf. | Fósínópríl lyfjasamsetning |
| AU2003240669B2 (en) * | 2002-05-17 | 2007-03-08 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| BG65538B1 (bg) * | 2002-07-05 | 2008-11-28 | "Софарма" Ад | Лекарствена форма на силимарин и метод за нейнотополучаване |
| AR047880A1 (es) * | 2004-02-17 | 2006-03-01 | Novartis Ag | COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS |
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| ATE493973T1 (de) * | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| WO2006041763A1 (en) * | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
| US8367105B2 (en) * | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| KR20080000624A (ko) | 2005-04-27 | 2008-01-02 | 노파르티스 아게 | 아테롬성동맥경화증의 치료 방법 |
| EP1940374A2 (en) * | 2005-10-21 | 2008-07-09 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
-
2006
- 2006-06-23 GB GBGB0612540.5A patent/GB0612540D0/en not_active Ceased
-
2007
- 2007-06-21 US US12/304,244 patent/US8618172B2/en active Active
- 2007-06-21 AU AU2007263261A patent/AU2007263261B2/en not_active Ceased
- 2007-06-21 RU RU2009101971/15A patent/RU2491058C2/ru not_active IP Right Cessation
- 2007-06-21 EP EP07785832.2A patent/EP2034968B1/en active Active
- 2007-06-21 AR ARP070102734A patent/AR061565A1/es unknown
- 2007-06-21 CA CA002654872A patent/CA2654872A1/en not_active Abandoned
- 2007-06-21 KR KR1020087031081A patent/KR101442272B1/ko not_active Expired - Fee Related
- 2007-06-21 BR BRPI0713338-3A patent/BRPI0713338A2/pt not_active IP Right Cessation
- 2007-06-21 MY MYPI20084990A patent/MY146779A/en unknown
- 2007-06-21 WO PCT/EP2007/005476 patent/WO2007147596A1/en not_active Ceased
- 2007-06-21 NZ NZ572937A patent/NZ572937A/en not_active IP Right Cessation
- 2007-06-21 CN CNA2007800225770A patent/CN101472566A/zh active Pending
- 2007-06-21 EP EP10191022A patent/EP2311439A1/en not_active Withdrawn
- 2007-06-21 JP JP2009515768A patent/JP5362556B2/ja not_active Expired - Fee Related
- 2007-06-21 MX MX2008016533A patent/MX2008016533A/es active IP Right Grant
- 2007-06-21 ES ES07785832T patent/ES2704979T3/es active Active
- 2007-06-21 EP EP18177693.1A patent/EP3391878A1/en not_active Withdrawn
- 2007-06-22 TW TW096122538A patent/TWI457137B/zh not_active IP Right Cessation
- 2007-06-22 PE PE2012000368A patent/PE20120990A1/es not_active Application Discontinuation
- 2007-06-22 PE PE2007000804A patent/PE20080373A1/es not_active Application Discontinuation
- 2007-06-22 CL CL200701837A patent/CL2007001837A1/es unknown
-
2008
- 2008-11-17 ZA ZA200809773A patent/ZA200809773B/xx unknown
- 2008-11-20 IL IL195425A patent/IL195425A/en not_active IP Right Cessation
- 2008-12-17 EC EC2008008986A patent/ECSP088986A/es unknown
- 2008-12-17 GT GT200800297A patent/GT200800297A/es unknown
- 2008-12-19 TN TNP2008000528A patent/TNSN08528A1/en unknown
- 2008-12-24 MA MA31502A patent/MA30527B1/fr unknown
-
2009
- 2009-01-16 NO NO20090262A patent/NO20090262L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2438661C2 (ru) | Галеновы составы органических соединений | |
| TWI388345B (zh) | 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 | |
| TWI407978B (zh) | 濕粒狀藥物之製備方法 | |
| JP2003231634A5 (enExample) | ||
| JP2009541239A5 (enExample) | ||
| JP2004532863A5 (enExample) | ||
| JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| EP3003276A1 (en) | Solid pharmaceutical dosage form | |
| JP5362556B2 (ja) | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 | |
| WO2018211479A1 (en) | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof | |
| CN102274223B (zh) | 含替米沙坦和氨氯地平的复方制剂 | |
| WO2014058047A1 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| RU2483718C2 (ru) | Галеновые композиции алискирена | |
| KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| JP2012503020A5 (enExample) | ||
| KR102314015B1 (ko) | 이층정제 및 이의 제조 방법 | |
| WO2010033954A2 (en) | Galenical formulations of organic compounds | |
| JP6363079B2 (ja) | アトルバスタチン、イルベサルタンおよび炭酸マグネシウムを含有する二層複合錠製剤 | |
| US20120009257A1 (en) | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren | |
| US20120003308A1 (en) | Pharmaceutical Composition Comprising Aliskiren | |
| KR20090096070A (ko) | 발사르탄 함유 경구 고형제의 신규 제조방법 |